---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-200247"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:21:15.994754+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verrica Q2 2024: YCANTH revenue $4.9M; net loss $17.2M; positive Phase 2 BCC data

## Summary
- Net product revenue of $4.9M from YCANTH; net loss $17.2M ($0.37/sh) vs $11.0M ($0.24/sh) in Q2 2023.
- Cash and equivalents $31.9M; expects runway into Q1 2025.
- Phase 2 VP-315: 51% complete histologic clearance of basal cell carcinoma; no serious adverse events.
- Permanent J-Code for YCANTH effective Apr 1; settlement with Dormer Labs to stop unapproved cantharidin sales in US.
- Amended Torii agreement: equal cost split for Phase 3 common warts trial; $8M milestone at first Japan patient dosed.

## SEC filing metadata
- accession: 0001193125-24-200247
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312524200247/0001193125-24-200247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312524200247/d857642d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-200247
- JSON: https://secwatch.observer/filing/0001193125-24-200247.json
- Plain text: https://secwatch.observer/filing/0001193125-24-200247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.